REPLIGEN CORP (RGEN) Stock Fundamental Analysis
USA - NASDAQ:RGEN - US7599161095 - Common Stock
123.37 USD
+3.98 (+3.33%)
RGEN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, there are worries on its profitability. While showing a medium growth rate, RGEN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year RGEN was profitable.
RGEN had a positive operating cash flow in the past year.
Of the past 5 years RGEN 4 years were profitable.
Each year in the past 5 years RGEN had a positive operating cash flow.
1.2 Ratios
RGEN has a Return On Assets (-0.48%) which is comparable to the rest of the industry.
RGEN has a better Return On Equity (-0.67%) than 61.82% of its industry peers.
RGEN's Return On Invested Capital of 0.57% is in line compared to the rest of the industry. RGEN outperforms 60.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 15.96%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.48% | ||
| ROE | -0.67% | ||
| ROIC | 0.57% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
The Operating Margin of RGEN (3.72%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of RGEN has declined.
RGEN's Gross Margin of 50.99% is in line compared to the rest of the industry. RGEN outperforms 56.36% of its industry peers.
RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.72% | ||
| PM (TTM) | N/A | ||
| GM | 50.99% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
RGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
RGEN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RGEN has been increased compared to 5 years ago.
The debt/assets ratio for RGEN has been reduced compared to a year ago.
2.2 Solvency
RGEN has an Altman-Z score of 5.65. This indicates that RGEN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of RGEN (5.65) is better than 85.45% of its industry peers.
The Debt to FCF ratio of RGEN is 5.04, which is a neutral value as it means it would take RGEN, 5.04 years of fcf income to pay off all of its debts.
RGEN has a Debt to FCF ratio of 5.04. This is in the better half of the industry: RGEN outperforms 69.09% of its industry peers.
RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of RGEN (0.26) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 5.65 |
ROIC/WACC0.06
WACC9.88%
2.3 Liquidity
A Current Ratio of 8.59 indicates that RGEN has no problem at all paying its short term obligations.
RGEN has a better Current ratio (8.59) than 89.09% of its industry peers.
A Quick Ratio of 7.32 indicates that RGEN has no problem at all paying its short term obligations.
The Quick ratio of RGEN (7.32) is better than 89.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.59 | ||
| Quick Ratio | 7.32 |
3. Growth
3.1 Past
RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.32%, which is quite impressive.
The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
The Revenue for RGEN has decreased by -11.36% in the past year. This is quite bad
RGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.62% yearly.
EPS 1Y (TTM)39.32%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%12.12%
Revenue 1Y (TTM)-11.36%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%18.36%
3.2 Future
Based on estimates for the next years, RGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 26.58% on average per year.
RGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.90% yearly.
EPS Next Y16.2%
EPS Next 2Y22.73%
EPS Next 3Y24.82%
EPS Next 5Y26.58%
Revenue Next Year14.56%
Revenue Next 2Y14.12%
Revenue Next 3Y14.51%
Revenue Next 5Y15.9%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 75.69, the valuation of RGEN can be described as expensive.
The rest of the industry has a similar Price/Earnings ratio as RGEN.
RGEN is valuated expensively when we compare the Price/Earnings ratio to 27.20, which is the current average of the S&P500 Index.
RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 55.34.
RGEN's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, RGEN is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 75.69 | ||
| Fwd PE | 55.34 |
4.2 Price Multiples
RGEN's Enterprise Value to EBITDA ratio is in line with the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGEN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 65.51 | ||
| EV/EBITDA | 51.95 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
RGEN's earnings are expected to grow with 24.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.67
PEG (5Y)10.65
EPS Next 2Y22.73%
EPS Next 3Y24.82%
5. Dividend
5.1 Amount
RGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RGEN (9/18/2025, 1:42:27 PM)
123.37
+3.98 (+3.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.6%
Inst Owner Change-11.04%
Ins Owners0.51%
Ins Owner Change-2.26%
Market Cap6.94B
Analysts80.71
Price Target183.05 (48.37%)
Short Float %6.9%
Short Ratio4.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.95%
Min EPS beat(2)-6.83%
Max EPS beat(2)10.73%
EPS beat(4)3
Avg EPS beat(4)8.75%
Min EPS beat(4)-6.83%
Max EPS beat(4)25.89%
EPS beat(8)4
Avg EPS beat(8)7.57%
EPS beat(12)8
Avg EPS beat(12)8.61%
EPS beat(16)12
Avg EPS beat(16)12.23%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)1.23%
Max Revenue beat(2)2.15%
Revenue beat(4)2
Avg Revenue beat(4)0.11%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)2
Avg Revenue beat(8)-0.75%
Revenue beat(12)3
Avg Revenue beat(12)-0.94%
Revenue beat(16)7
Avg Revenue beat(16)0.86%
PT rev (1m)-0.31%
PT rev (3m)-2.26%
EPS NQ rev (1m)0.29%
EPS NQ rev (3m)4.34%
EPS NY rev (1m)0.35%
EPS NY rev (3m)0.64%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)3.55%
Revenue NY rev (1m)2.33%
Revenue NY rev (3m)2.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 75.69 | ||
| Fwd PE | 55.34 | ||
| P/S | 10.3 | ||
| P/FCF | 65.51 | ||
| P/OCF | 52.54 | ||
| P/B | 3.37 | ||
| P/tB | 12.82 | ||
| EV/EBITDA | 51.95 |
EPS(TTM)1.63
EY1.32%
EPS(NY)2.23
Fwd EY1.81%
FCF(TTM)1.88
FCFY1.53%
OCF(TTM)2.35
OCFY1.9%
SpS11.98
BVpS36.65
TBVpS9.63
PEG (NY)4.67
PEG (5Y)10.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.48% | ||
| ROE | -0.67% | ||
| ROCE | 0.9% | ||
| ROIC | 0.57% | ||
| ROICexc | 0.76% | ||
| ROICexgc | 2.86% | ||
| OM | 3.72% | ||
| PM (TTM) | N/A | ||
| GM | 50.99% | ||
| FCFM | 15.72% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexcg growth 3Y-71.22%
ROICexcg growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score4
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 4.24 | ||
| Cap/Depr | 25.94% | ||
| Cap/Sales | 3.88% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 104.92% | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.59 | ||
| Quick Ratio | 7.32 | ||
| Altman-Z | 5.65 |
F-Score4
WACC9.88%
ROIC/WACC0.06
Cap/Depr(3y)88.31%
Cap/Depr(5y)109.53%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.32%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%12.12%
EPS Next Y16.2%
EPS Next 2Y22.73%
EPS Next 3Y24.82%
EPS Next 5Y26.58%
Revenue 1Y (TTM)-11.36%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%18.36%
Revenue Next Year14.56%
Revenue Next 2Y14.12%
Revenue Next 3Y14.51%
Revenue Next 5Y15.9%
EBIT growth 1Y451.21%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year72.43%
EBIT Next 3Y40.62%
EBIT Next 5Y37.42%
FCF growth 1Y10.02%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-11.28%
OCF growth 3Y13.8%
OCF growth 5Y21.15%